CDNA 8-K/A

CareDx, Inc. (CDNA)

8-K/A 2026-02-25 For: 2026-02-24

View Original

Added on April 04, 2026



Exhibit No.						Description

99.1						Press Release issued by CareDx, Inc., dated February 24, 2026.
104						Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).



		CAREDX, INC.

Date: February 25, 2026	By:	/s/ JOHN HANNA
		John W. Hanna
		President, Chief Executive Officer and Director


	Three Months Ended December 31,				Twelve Months Ended December 31,
	2025		2024		2025		2024
Revenue:
Testing services revenue	$	78,373	$	63,819	$	274,495	$	249,381
Product revenue	13,256		11,367		48,377		40,783
Patient and digital solutions revenue	16,757		11,393		56,933		43,621
Total revenue	108,386		86,579		379,805		333,785
Operating expenses:
Cost of testing services	16,821		14,224		62,045		55,611
Cost of product	6,757		5,580		22,953		23,381
Cost of patient and digital solutions	11,934		8,392		38,241		30,704
Research and development	19,306		16,614		71,429		72,510
Sales and marketing	30,924		21,341		102,643		81,975
General and administrative	28,684		32,349		107,565		125,139
Litigation settlement expense	—		(96,300)		5,710		(96,300)
Total operating expenses	114,426		2,200		410,586		293,020
(Loss) income from operations	(6,040)		84,379		(30,781)		40,765
Other income:
Interest income, net	2,013		3,053		9,174		11,765

Other income, net	264		436		524		329
Total other income	2,277		3,489		9,698		12,094
(Loss) income before income taxes	(3,763)		87,868		(21,083)		52,859
Income tax expense	(345)		(171)		(271)		(310)
Net (loss) income	$	(4,109)	$	87,697	$	(21,354)	$	52,549
Net (loss) income per share (Note 3):
Basic	$	(0.08)	$	1.62	$	(0.40)	$	1.00
Diluted	$	(0.08)	$	1.51	$	(0.40)	$	0.93
Weighted-average shares used to compute net (loss) income per share:
Basic	51,124,846		54,283,644		53,287,546		52,773,247
Diluted	51,124,846		58,221,755		53,287,546		56,620,590


	As of December 31,
	2025		2024
Assets
Current assets:
Cash and cash equivalents	$	65,429	$	114,689
Marketable securities	111,779		145,964
Accounts receivable	42,628		64,605
Inventory	26,705		19,503
Prepaid and other current assets	10,591		7,071
Total current assets	257,132		351,832
Property and equipment, net	32,971		33,552
Operating lease right-of-use assets	22,760		24,340
Marketable securities, non-current	24,165		—
Intangible assets, net	31,960		38,184
Goodwill	40,336		40,336
Restricted cash	551		585
Other assets	3,353		2,221
Total assets	$	413,228	$	491,050
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	9,988	$	7,686
Accrued compensation	38,107		38,333
Accrued and other liabilities	41,754		43,352
Total current liabilities	89,849		89,371
Deferred tax liability	181		164


Contingent consideration	161		174
Operating lease liabilities, less current portion	19,679		22,263
Other liabilities	257		645
Total liabilities	110,127		112,617
Commitments and contingencies
Stockholders’ equity:
Common stock	50		51
Additional paid-in capital	1,043,925		1,013,193
Accumulated other comprehensive loss	(5,515)		(8,569)
Accumulated deficit	(735,359)		(626,242)
Total stockholders’ equity	303,101		378,433
Total liabilities and stockholders’ equity	$	413,228	$	491,050


	Three Months Ended December 31,				Twelve Months Ended December 31,
	2025		2024		2025		2024
Cost of testing services reconciliation:
GAAP cost of testing services	$	16,821	$	14,224	$	62,045	$	55,611
Stock-based compensation expense	(272)		(328)		(1,263)		(1,560)
Restructuring costs	—		—		(120)		—
Acquisition related-amortization of purchased intangibles	(347)		(329)		(1,386)		(1,316)
Non-GAAP cost of testing services	$	16,202	$	13,567	$	59,276	$	52,735
Cost of product reconciliation:
GAAP cost of product	$	6,757	$	5,580	$	22,953	$	23,434
Stock-based compensation expense	(73)		(94)		(464)		(870)
Acquisition related-amortization of purchased intangibles	(451)		(410)		(1,751)		(1,660)
Restructuring costs	—		—		(175)		(53)
Non-GAAP cost of product	$	6,233	$	5,076	$	20,563	$	20,851
Cost of patient and digital solutions reconciliation:
GAAP cost of patient and digital solutions	$	11,934	$	8,392	$	38,241	$	30,656
Stock-based compensation expense	(96)		(228)		(624)		(1,276)
Acquisition related-amortization of purchased intangibles	(152)		(171)		(610)		(850)
Restructuring costs	—		(18)		(166)		(18)
Other income	—		—		—		5
Non-GAAP cost of patient and digital solutions	$	11,686	$	7,975	$	36,841	$	28,517
Research and development expenses reconciliation:
GAAP research and development expenses	$	19,306	$	16,614	$	71,429	$	72,504
Stock-based compensation expense	(1,131)		(1,338)		(5,043)		(6,501)
Restructuring costs	—		(84)		(174)		(99)

Other charges	—		—		—		(25)
Non-GAAP research and development expenses	$	18,175	$	15,192	$	66,212	$	65,879
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses	$	30,924	$	21,341	$	102,643	$	81,975
Stock-based compensation expense	(1,579)		(2,278)		(8,091)		(11,035)
Acquisition related-amortization of purchased intangibles	(671)		(625)		(2,602)		(2,520)
Transformational initiative costs*	(429)		—		(612)		—
Restructuring costs	—		(257)		(221)		(257)
Other charges	—		—		—		(8)
Non-GAAP sales and marketing expenses	$	28,245	$	18,181	$	91,117	$	68,155
General and administrative expenses reconciliation:
GAAP general and administrative expenses	$	28,684	$	(63,951)	$	113,275	$	28,840
Stock-based compensation expense	(4,939)		(12,245)		(19,380)		(45,164)
Change in estimated fair value of contingent consideration	(156)		(170)		(703)		(931)
Acquisition related fees and expenses	—		—		(204)		(40)
Litigation settlement expense	—		96,300		(5,710)		96,300
Restructuring costs	—		(1,356)		(34)		(1,356)
Transformational initiative costs*	—		—		(2,212)		—
Impairment of intangible asset	—		—		(2,258)		—
Other income (charges)	$	—	$	—	$	—	$	22
Non-GAAP general and administrative expenses	$	23,589	$	18,578	$	82,774	$	77,671




Total other income reconciliation:
GAAP other income	$	2,277	$	3,489	$	9,698	$	12,094


Other income	—		(500)		—		(500)
Non-GAAP other income	$	2,277	$	2,989	$	9,698	$	11,594
Income tax benefit (expense) reconciliation:
GAAP income tax expense	$	(345)	$	(171)	$	(271)	$	(310)
Tax effect related to amortization of purchased intangibles	(112)		(98)		(431)		(400)
Non-GAAP income tax expense	$	(457)	$	(269)	$	(702)	$	(710)


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))